SouthEastern Vascular Study Group (SEVSG)

September 25, 2020
10:00 am-12:30 am ET
Remote
Participation Award Credit

PLEASE SIGN IN!!!

Click “Participants” in the box at the top or bottom of your screen. If your full name is not listed, hover next to your name and you’ll see “rename”. Click and sign in. If you can’t sign in, please email Leka Johnson at ljohson@svpso.org and let her know the identifier you were signed in under (ex –LM7832 or your phone number).

**SPECIAL NOTE: We do give credit to residents/fellows that don’t have a pathways user account !!!
Sign in with your Full name, MD, Name of Institution
## Agenda

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>CE Credit</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00am</td>
<td>Welcome</td>
<td>No</td>
</tr>
<tr>
<td>10:10am</td>
<td>Regional Data Review</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Charles Ross, MD, Regional Medical Director, SEVSG</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Learning Objectives:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Use the VQI regional reports to establish quality improvement goals for the vascular patients (outcomes) and for their center (process).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Interpret and compare each centers’ VQI results to regional and national benchmarked data.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Learn, through group discussion the VQI regional results to improve the quality of vascular health care by monitoring measurable performance indicators, SVS PSO evidence-based research, and outcomes.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify high performing regional vascular centers to discuss variations in care and clinical practice patterns to improve outcomes and prompt quality improvement recommendations for vascular care patients. Sharing of best practices/pathways of care.</td>
<td></td>
</tr>
<tr>
<td>11:10 am</td>
<td>Regional QI Proposal</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Charles Ross, MD, Regional Medical Director, SEVSG</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Learning Objectives:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Use the VQI regional reports to establish quality improvement goals for the vascular patients (outcomes) and for their center (process).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Interpret and compare each centers’ VQI results to regional and national benchmarked data.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Learn, through group discussion the VQI regional results to improve the quality of vascular health care by monitoring measurable performance indicators, SVS PSO evidence-based research, and outcomes.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify high performing regional vascular centers to discuss variations in care and clinical practice patterns to improve outcomes and prompt quality improvement recommendations for vascular care patients. Sharing of best practices/pathways of care.</td>
<td></td>
</tr>
</tbody>
</table>
## Agenda (con’t)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>CE Credit</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30am</td>
<td><strong>National VQI Update</strong>&lt;br&gt;Caroline Morgan, BSN, Clinical Associate, PSO&lt;br&gt;Learning Objectives:&lt;br&gt;• Use the VQI regional reports to establish quality improvement goals for the vascular patients (outcomes) and for their center (process).&lt;br&gt;• Identify high performing regional vascular centers to discuss variations in care and clinical practice patterns to improve outcomes and prompt quality improvement recommendations for vascular care patients.&lt;br&gt;Sharing of best practices/pathways of care.</td>
<td>Yes</td>
</tr>
<tr>
<td>12:10am</td>
<td><strong>AQC Update</strong> – Adam Beck, MD</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td><strong>VQC Update</strong> – Olamide Alabi, MD</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td><strong>RAC Update</strong> – Emily Spangler, MD</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td><strong>Governing Council Update</strong> – Charles Ross, MD</td>
<td>No</td>
</tr>
<tr>
<td>12:30pm</td>
<td><strong>Open Discussion/Next Meeting/Meeting Evaluation</strong></td>
<td>No</td>
</tr>
</tbody>
</table>
AdventHealth Celebration
AdventHealth Orlando
AdventHealth Tampa
Albany Vascular Specialist Center
AU Medical Center
Baptist Hospital of Miami
Bartow Regional Medical Center
Bayfront Health Seven Rivers
Birmingham St. Vincent’s East Hospital
Brookwood Medical Center
Cape Canaveral Hospital
Cardiothoracic and Vascular Surgical Associates
Central Florida Regional Hospital
Coastal Vascular & Interventional, PLLC
Coastal Vein and Vascular Specialists
Cobb Hospital
Delray Medical Center
East Alabama Medical Center
Emory St. Joseph’s Hospital
Florida Hospital Memorial Medical Center
Florida Hospital Zephyrhills
Floyd Medical Center
Grady Memorial Hospital (GA)
Gulf Coast Medical Center
Halifax Hospital Medical Center
Health Park Medical Center
Holmes Regional Medical Center
Huntsville Hospital
Kennebunk Hospital
Lakeland Regional Medical Center
Lyerly Baptist Neurosurgery
Martin Medical Center
Mayo Clinic Florida
Mease Countryside Hospital
Mease Dunedin Hospital
Medical Center Navicent Healthcare
Memorial Health University Medical Center
Memorial Hospital Pembroke
Memorial Hospital West
Memorial Regional Hospital
Miami Vein Center
Mobile Infirmary
Morton Plant Hospital
Morton Plant North Bay
Mount Sinai Medical Center
North Florida Regional Medical Center
North Okaloosa Medical Center
Northeast Georgia Medical Center, Inc.
Northside Hospital Atlanta
Northside Hospital Cherokee
Northside Hospital Forsyth
Ocala Regional Medical Center
Orlando Health - Dr. P. Phillips Hospital
Orlando Health - Health Central Hospital
Orlando Health - Orlando Regional
Orlando Health - South Seminole Hospital
Piedmont Athens Regional Medical Center
Piedmont Hospital
Providence Hospital
Redmond Regional Medical Center
Rush Foundation Hospital
Saint Joseph’s Hospital/Candler
Saint Luke’s Memorial Hospital, Inc.
Sarasota Memorial Hospital
South Florida Baptist
South Miami Hospital
Space Coast Vascular
St. Anthony's Hospital-FL
St. Joseph's Hospital North
St. Joseph's Hospital South
St. Joseph's Hospital-FL
Surgical Specialists of Central Florida
Tallahassee Memorial HealthCare, Inc
Tampa General Hospital
Tenet Florida Physicians Services
The Emory Clinic
The Vein and Vascular Institute of Tampa Bay
Tift Regional Medical Center
Tradition Medical Center
University Of Alabama Medical Center
University of Florida, Gainesville
Vascular & General Surgical Specialists of SWFL
Vascular Associates Of South Alabama, LLC
Vascular Surgery Associates
Venice Regional Bayfront Hospital
Winter Haven Hospital
Relevant to the content of this educational activity, the following individual(s) do not have a conflict with commercial interest to disclose:

- Charles Ross, MD, Regional Medical Director SEVSG
- Carrie Bosela, RN, CPC, CPC-I, Senior Director of Clinical Operations, PSO
- Caroline Morgan, BSN, Clinical Associate, PSO
VQI Regional Quality Report

Fall 2020

Important Notes

• All results are based on data entered into the VQI as of June 30th, 2020. Any subsequent changes or updates to data after that date will not be reflected in this report.
• For a given module, regions must have at least 3 centers with at least 10 cases per center meeting inclusion criteria in order for regional data (both aggregate and by center) to be displayed.
• For a given module, cases with missing data elements used in the construction of inclusion/exclusion criteria or outcomes are excluded.
• Please reference the “VQI Case Appendix” in the table of contents on the left to identify your center’s included or excluded cases for each module.
• In all graphics, "**" indicates a p-value <.05.

This report is patient safety work product generated within the SVS PSO, LLC, and is considered privileged and confidential.
Dashboard

The dashboard summarizes your center’s results for each module and provides regional and VQI-wide benchmarks for comparison. The “Your Center” column gives the percentage of your center’s cases with the noted outcome. Numbers in parentheses give the number of cases with the outcome and the total number of cases meeting the inclusion criteria for that module. The “Your Region” and “VQI Overall” columns give the aggregate percentage of cases with the noted outcome, as well as the 25th, 50th (median), and 75th percentiles, for centers in your region and VQI, respectively. Percentiles are ordered so that a higher percentile indicates better performance. Your center’s results are highlighted green if your center is at or above the 75th percentile across VQI, yellow if among the middle 50% of centers in VQI, and red if at or below the 25th percentile across VQI. For details on a particular module, click on the module report name in the table of contents on the left.

Legend:  Green = At or above 75th percentile  Yellow = Middle 50%  Red = At or below 25th percentile
| Procedure Group | Outcome                        | Your Center % (n/N) | Your Region % [25p|50p|75p] | VQI Overall % [25p|50p|75p] |
|-----------------|--------------------------------|---------------------|------------------------------|-----------------------------|
|                 | Procedure Volume               |                     | [16 | 65 | 146]                     | [20 | 88 | 229]                      |
|                 | Procedure Volume, All Years    |                     | [30 | 194 | 979]                    | [50 | 339 | 1334]                     |
| Multiple        | Long-Term Follow-up            | 56% [40% | 63% | 75%] | 68.3% [45% | 71% | 87%]       |
|                 | Discharge Medications          | 78.7% [73% | 84% | 92%] | 84.8% [79% | 86% | 96%]       |
| TFEM CAS ASYMP  | Stroke/Death                   | NA (<3 centers)    | 1.2% [0% | 0% | 0%]   | 3.6% [0% | 0% | 0%]   |
| TFEM CAS SYMP   | Stroke/Death                   | 3.8% [0% | 0% | 0%]   | 3.6% [0% | 0% | 0%]   |
| TCAR ASYMP      | Stroke/Death                   | 0.4% [0% | 0% | 0%]   | 1% [0% | 0% | 0%]   |
| TCAR SYMP       | Stroke/Death                   | 1.4% [0% | 0% | 0%]   | 3% [0% | 0% | 0%]   |
| CEA ASYMP       | Stroke/Death                   | 0.5% [0% | 0% | 0%]   | 0.9% [0% | 0% | 0%]   |
|                 | Postop LOS>1 Day               | 26.7% [41% | 21% | 12%] | 23.3% [33% | 21% | 12%]       |
| CEA SYMP        | Stroke/Death                   | 1.4% [0% | 0% | 0%]   | 1.7% [0% | 0% | 0%]   |
|                 | Postop LOS>1 Day               | 47.7% [69% | 51% | 29%] | 43% [59% | 40% | 27%]       |
| EVAR            | Postop LOS>2 Days              | 18.8% [28% | 15% | 5%]  | 14.2% [20% | 13% | 5%]       |
|                 | Sac Diameter Reporting        | 53.6% [33% | 55% | 71%] | 58.6% [38% | 64% | 79%]       |
| SVS Sac Size Guideline | Sac Diameter Reporting       | 71.3% [65% | 79% | 100%] | 73.4% [62% | 75% | 87%]       |
| TEVAR           | Sac Diameter Reporting        | 51.8% [25% | 57% | 68%]  | 56.7% [22% | 55% | 73%]       |
| OAAA            | In-Hospital Mortality          | 3.7% [1% | 0% | 0%]   | 4.2% [1% | 0% | 0%]   |
| SVS Cell-Saver Guideline | Sac Diameter Reporting       | 97.5% [100% | 100% | 100%] | 93.3% [95% | 100% | 100%]       |
| SVS Iliac Inflow Guideline | Sac Diameter Reporting       | 95.7% [95% | 100% | 100%] | 98.8% [100% | 100% | 100%]       |
| PVI             | ABI/Toe Pressure               | 46.9% [0% | 31% | 74%]   | 74.6% [60% | 84% | 94%]       |
| INFRA           | Major Complications            | 3.5% [4% | 0% | 0%]   | 4.1% [6% | 0% | 0%]   |
| SUPRA           | Major Complications            | 3.3% [0% | 0% | 0%]   | 5.2% [0% | 0% | 0%]   |
| LEAMP           | Postop Complications           | 7.6% [10% | 8% | 5%]    | 12% [18% | 10% | 5%]    |
| AVACCESS        | Primary AVF vs. Graft          | 68.9% [66% | 69% | 89%] | 82.1% [72% | 85% | 92%]       |
| IVCF            | Filter Retrieval Reporting     | 9.1% [0% | 24% | 33%]   | 22.8% [0% | 1% | 33%]   |
### Procedure Volume, All Years

Includes all procedures with procedure date through May 31, 2020

Number of cases entered into the VQI, by registry and overall

<table>
<thead>
<tr>
<th></th>
<th>Your Center (N)</th>
<th>Your Region (N)</th>
<th>VQI Overall (N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVACCESS</td>
<td>5115</td>
<td>54564</td>
<td></td>
</tr>
<tr>
<td>CAS (TFEM CAS &amp; TCAR)</td>
<td>3689</td>
<td>41682</td>
<td></td>
</tr>
<tr>
<td>CEA</td>
<td>11226</td>
<td>139597</td>
<td></td>
</tr>
<tr>
<td>EVAR</td>
<td>3650</td>
<td>55124</td>
<td></td>
</tr>
<tr>
<td>INFRA</td>
<td>4603</td>
<td>59556</td>
<td></td>
</tr>
<tr>
<td>IVCF</td>
<td>1289</td>
<td>14022</td>
<td></td>
</tr>
<tr>
<td>LEAMP</td>
<td>2036</td>
<td>17738</td>
<td></td>
</tr>
<tr>
<td>OAAA</td>
<td>866</td>
<td>13439</td>
<td></td>
</tr>
<tr>
<td>PVI</td>
<td>12468</td>
<td>225515</td>
<td></td>
</tr>
<tr>
<td>SUPRA</td>
<td>1663</td>
<td>19457</td>
<td></td>
</tr>
<tr>
<td>TEVAR</td>
<td>1728</td>
<td>17236</td>
<td></td>
</tr>
<tr>
<td>Varicose Veins</td>
<td>2773</td>
<td>38407</td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>51106</td>
<td>696337</td>
<td></td>
</tr>
</tbody>
</table>
Procedure Volume by Center in Your Region (Through May 2020)

Centers (centers with <10 cases not shown)

Procedure Volume Across VQI (Through May 2020)

Regions (regions with <3 centers with at least 10 cases not shown)

"Others" indicates centers that do not belong to a regional group.
Physician Specialties

Physician Specialties Across VQI (as of June 30, 2020, N=5156 Physicians)

- Vascular Surgery: 50%
- Radiology: 40%
- Cardiology: 35%
- Other: 30%
- General Surgery: 25%
- Cardiothoracic Surgery: 20%
- Neurosurgery: 15%
- None: 10%

0%
Physician Specialties Across Your Region (as of June 30, 2020, N=492 Physicians)
Long-Term Follow-up

Procedures performed between July 1, 2017 and June 30, 2018

Includes AVACCESS, CAS (TFEM CAS and TCAR), CEA, EVAR, INFRA, IVCF, LEAMP, OAAA, PVI, SUPRA, and TEVAR procedures only. Excludes cases not eligible for long-term follow-up.

The table below gives the number of procedures meeting the inclusion criteria, and the percentage of those procedures with follow-up recorded between 9 and 21 months post-procedure.

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVACCESS</td>
<td>786 (54%)</td>
<td>7949 (59%)</td>
<td></td>
</tr>
<tr>
<td>CAS</td>
<td>603 (63%)</td>
<td>6442 (65%)</td>
<td></td>
</tr>
<tr>
<td>CEA</td>
<td>1570 (59%)</td>
<td>18395 (70%)</td>
<td></td>
</tr>
<tr>
<td>EVAR</td>
<td>508 (64%)</td>
<td>7337 (78%)</td>
<td></td>
</tr>
<tr>
<td>INFRA</td>
<td>668 (56%)</td>
<td>7463 (70%)</td>
<td></td>
</tr>
<tr>
<td>IVCF</td>
<td>156 (72%)</td>
<td>2153 (71%)</td>
<td></td>
</tr>
<tr>
<td>LEAMP</td>
<td>533 (45%)</td>
<td>3143 (63%)</td>
<td></td>
</tr>
<tr>
<td>OAAA</td>
<td>97 (54%)</td>
<td>1200 (72%)</td>
<td></td>
</tr>
<tr>
<td>PVI</td>
<td>1942 (52%)</td>
<td>32437 (70%)</td>
<td></td>
</tr>
<tr>
<td>SUPRA</td>
<td>231 (47%)</td>
<td>2368 (67%)</td>
<td></td>
</tr>
<tr>
<td>TEVAR</td>
<td>244 (62%)</td>
<td>2502 (66%)</td>
<td></td>
</tr>
<tr>
<td>Overall (July 2017-June 2018)</td>
<td>7338 (56%)</td>
<td>91389 (68%)</td>
<td></td>
</tr>
<tr>
<td>Overall (July 2016-June 2017)</td>
<td>5806 (66%)</td>
<td>80731 (73%)</td>
<td></td>
</tr>
</tbody>
</table>
Discharge Medications

Procedures performed between June 1, 2019 and May 31, 2020

Includes CAS (TFEM CAS and TCAR), CEA, EVAR, INFRA, LEAMP, OAAA, PVI, SUPRA, and TEVAR procedures only. Excludes patients who died in hospital or patients who were not treated for medical reason. “Antiplatelet” is defined as ASA or P2Y12 inhibitor.

The table below gives the number of procedures meeting the inclusion criteria, and the percentage of those procedures where patients received discharge medications.

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Number of Procedures at Your Center</th>
<th>Antiplatelet+Statin</th>
<th>Antiplatelet Only</th>
<th>Statin Only</th>
<th>Neither</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CEA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVAR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INFRA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LEAMP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OAAA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PVI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SUPRA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TEVAR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Your Center Overall</td>
<td>7022</td>
<td>79%</td>
<td>12%</td>
<td>5%</td>
<td>4%</td>
</tr>
<tr>
<td>Your Region Overall</td>
<td>80978</td>
<td>85%</td>
<td>9%</td>
<td>4%</td>
<td>2%</td>
</tr>
<tr>
<td>VQI Overall</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Discharge Antiplatelet+Statin by Center in Your Region (June 2019-May 2020)

- **Other centers in your region**
- **Your center**

**Centers (centers with <10 cases not shown)**

"*** indicates center's rate differs significantly from the regional rate."

Discharge Antiplatelet+Statin by Region Across VQI (June 2019-May 2020)

- **Southeast**
- **Rocky Mtns**
- **New York**
- **Mid-Atlantic**
- **Canada**
- **Virginia**
- **SoVONet**
- **VQI**
- **Nor. Cal.**
- **Pacif. NW**
- **So. Cal.**
- **G. Lakes**
- **Others**
- **Midwest**
- **MidSoth**
- **Up**
- **Midwest**
- **Carolinas**
- **Michigan**
- **Mid-America**
- **New England**

"Others" indicates centers that do not belong to a regional group. "*** indicates region's rate differs significantly from the VQI rate."
Quality Improvement

Use of Discharge Medications

National QI initiative – Use of Discharge Medications

As part of the QI process, vascular specialists are encouraged to communicate with primary care physicians, patients, and other providers regarding the use of discharge medications.

Below please see links to sample communications currently in use within the VQI:

Discharge Meds Webinar
Reference List for Discharge Meds 7/20/2017
Discharge Medications – 5-Year Survival Flyer (courtesy of Randy DeMartino, MD)

Risk Factor Modification
Risk Factor Modification Letter – Patient
Risk Factor Modification Letter – Physician

Sample Letters by Type of Medication (Hospital Setting)

Aspirin
Letter to Patient
Letter to Physician

ACE Inhibitor
Letter to Patient
Letter to Physician

Beta Block
Letter to Patient
Letter to Physician

Statin
Letter to Patient
Letter to Physician

Quality Improvement Updates

RECENT WEBINARS:
“Starting a QI Project” (3/26/2020)
Click here to view this Webinar

“Vascular Medicine Consult Webinar” (1/21/20)
Click here to view this Webinar

“Varicose Vein Registry Update” (12/2019)
Click here to view this Webinar

“Wrapping up a QI Project” (12/2019)
Click here to view this Webinar

“QI Webinar – Long-Term Follow Up Success Stories and Tools”
Click here to view this Webinar

LATEST QI E-NEWSLETTER:
QI Newsletter - May 2020

LATEST VQI NEWS:
VQI Newsletter - July 2020 Issue
Dear Dr. ______________,

We had the pleasure of participating in the care of ____________________ while _______________________ was hospitalized recently at ______________________ hospital. In our medication review we found that he/she is not on statin therapy. A growing body of literature, as summarized in a meta-analysis¹, has demonstrated that statin therapy is beneficial in reducing morbidity and mortality in patients with peripheral vascular disease (PAD). This benefit has been shown to extend to patients undergoing carotid surgery, lower extremity bypass surgery, and abdominal aortic aneurysm surgery, regardless of cholesterol level.

Accordingly, during the hospitalization, we started our shared patient on simvastatin 40mg daily. This initiative to optimize statin use in patients with vascular disease is a component of the Southern California Vascular Outcomes Improvement Collaborative (So Cal VOICE), in which I am a member and active participant. The So Cal VOICE is a regional voluntary cooperative group of vascular disease specialists dedicated to improving outcomes and advancing the care of vascular patients. Our regional group is part of a national network of quality improvement organizations sponsored by the Society for Vascular Surgery.

We sent a baseline liver function panel today and have asked him/her to follow up with you in four to six weeks for repeat liver function studies. As always, if you have any questions please contact me at ______________, and I would be happy to speak with you.

Sincerely,
TFEM CAS ASYMP: Stroke/Death

Procedures performed between June 1, 2019 and May 31, 2020

Includes asymptomatic admissions for Transfemoral Carotid Artery Stenting (TFEM CAS) only. Asymptomatic admissions are admissions where the patient had no ipsilateral or contralateral retinal or cortical TIA or stroke within 180 days prior to surgery. Excludes any patient with prior vertebrobasilar TIA or stroke, prior ipsilateral CAS, CAS for intracranial treatment, or any procedure involving dissection, trauma, FMD, or “Other” lesion types. Procedures with an approach other than “Femoral” are also excluded.

The table below gives the number of TFEM CAS procedures (performed on asymptomatic admissions) meeting the inclusion criteria, and the observed and expected rates of in-hospital stroke or death for those cases.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of TFEM CAS procedures meeting inclusion criteria</td>
<td>NA (&lt;3 centers)</td>
<td>1205</td>
<td></td>
</tr>
<tr>
<td>Observed rate of stroke or death among procedures meeting inclusion criteria</td>
<td>1.2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of procedures with complete data*</td>
<td>1116</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Observed rate of stroke or death among cases with complete data</td>
<td>1.3%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expected rate of stroke or death among cases with complete data*</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-value for comparison of observed and expected rates</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*“Expected rate” is the rate estimated by a statistical model that accounts for patient characteristics, including age, gender, race, BMI, comorbidities, medication and stroke and vascular history. “Cases with complete data” include patients who have data on all of those factors.
Stroke or Death After TFEM CAS for Asymptomatic Admissions by Year

Rates shown are observed rates among cases meeting inclusion criteria.
Stroke or Death After TFEM CAS for Asymptomatic Admissions in Your Region (June 2019-May 2020)

- Other centers in your region
- Your center
- Observed
- Expected

Centers (centers with <10 complete cases not shown)

Observed and expected rates shown are among cases with complete data. Regional data suppression is based on number of complete cases. **"** indicates center's observed rate differs significantly from its expected rate.

Stroke or Death After TFEM CAS for Asymptomatic Admissions by Region Across VQI (June 2019-May 2020)

- Observed
- Expected

Regions (regions with <3 centers with at least 10 complete cases not shown)

Observed and expected rates shown are among cases with complete data. Regional data suppression is based on number of complete cases. **"** indicates region's observed rate differs significantly from its expected rate.
**TFEM CAS SYMP: Stroke/Death**

Procedures performed between June 1, 2019 and May 31, 2020

Includes symptomatic admissions for Transfemoral Carotid Artery Stenting (TFEM CAS) only. Symptomatic admissions are admissions where the patient had an ipsilateral or contralateral retinal or cortical TIA or stroke within 180 days prior to surgery. Excludes any patient with prior vertebrobasilar TIA or stroke, prior ipsilateral CAS, CAS for intracranial treatment, or any procedure involving dissection, trauma, FMD, or “Other” lesion types. Procedures with an approach other than “Femoral” are also excluded.

The table below gives the number of TFEM CAS procedures (performed on symptomatic admissions) meeting the inclusion criteria, and the observed and expected rates of in-hospital stroke or death for those cases.

<table>
<thead>
<tr>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of TFEM CAS procedures meeting inclusion criteria</td>
<td>104</td>
<td>1407</td>
</tr>
<tr>
<td>Observed rate of stroke or death among procedures meeting inclusion criteria</td>
<td>3.8%</td>
<td>3.6%</td>
</tr>
<tr>
<td>Number of procedures with complete data*</td>
<td>99</td>
<td>1317</td>
</tr>
<tr>
<td>Observed rate of stroke or death among cases with complete data</td>
<td>4%</td>
<td>3.1%</td>
</tr>
<tr>
<td>Expected rate of stroke or death among cases with complete data*</td>
<td>3.8%</td>
<td>NA</td>
</tr>
<tr>
<td>P-value for comparison of observed and expected rates</td>
<td>0.79</td>
<td>NA</td>
</tr>
</tbody>
</table>

*"Expected rate" is the rate estimated by a statistical model that accounts for patient characteristics, including age, gender, race, BMI, comorbidities, medication and stroke and vascular history. "Cases with complete data" include patients who have data on all of those factors.
Stroke or Death After TFEM CAS for Symptomatic Admissions by Year

Rates shown are observed rates among cases meeting inclusion criteria.
Stroke or Death After TFEM CAS for Symptomatic Admissions in Your Region (June 2019-May 2020)

Observed and expected rates shown are among cases with complete data. Regional data suppression is based on number of complete cases. "***" Indicates center’s observed rate differs significantly from its expected rate.

Stroke or Death After TFEM CAS for Symptomatic Admissions by Region Across VQI (June 2019-May 2020)

Observed and expected rates shown are among cases with complete data. Regional data suppression is based on number of complete cases. "***" Indicates region’s observed rate differs significantly from its expected rate.
TCAR ASYMP: Stroke/Death

Procedures performed between June 1, 2019 and May 31, 2020

Includes asymptomatic admissions for TransCarotid Artery Revascularization (TCAR) only. Asymptomatic admissions are admissions where the patient had no ipsilateral or contralateral retinal or cortical TIA or stroke within 180 days prior to surgery. Excludes any patient with prior vertebrobasilar TIA or stroke, prior ipsilateral CAS, CAS for intracranial treatment, or any procedure involving dissection, trauma, FMD, or “Other” lesion types. Procedures with an approach other than “Femoral” are also excluded.

The table below gives the number of TCAR procedures (performed on asymptomatic admissions) meeting the inclusion criteria, and the observed and expected rates of in-hospital stroke or death for those cases.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of TCAR procedures meeting inclusion criteria</td>
<td>499</td>
<td></td>
<td>3627</td>
</tr>
<tr>
<td>Observed rate of stroke or death among procedures meeting inclusion criteria</td>
<td>0.4%</td>
<td>1%</td>
<td></td>
</tr>
<tr>
<td>Number of procedures with complete data*</td>
<td>448</td>
<td></td>
<td>3424</td>
</tr>
<tr>
<td>Observed rate of stroke or death among cases with complete data</td>
<td>0.4%</td>
<td>1%</td>
<td></td>
</tr>
<tr>
<td>Expected rate of stroke or death among cases with complete data*</td>
<td></td>
<td>1%</td>
<td>NA</td>
</tr>
<tr>
<td>P-value for comparison of observed and expected rates</td>
<td>0.46</td>
<td></td>
<td>NA</td>
</tr>
</tbody>
</table>

*“Expected rate” is the rate estimated by a statistical model that accounts for patient characteristics, including age, gender, race, BMI, comorbidities, medication and stroke and vascular history. “Cases with complete data” include patients who have data on all of those factors.
Stroke or Death After TCAR for Asymptomatic Admissions by Year

Rates shown are observed rates among cases meeting inclusion criteria.
Stroke or Death After TCAR for Asymptomatic Admissions in Your Region (June 2019-May 2020)

Observed and expected rates shown are among cases with complete data. Regional data suppression is based on number of complete cases.

*** indicates center's observed rate differs significantly from its expected rate.

Stroke or Death After TCAR for Asymptomatic Admissions by Region Across VQI (June 2019-May 2020)

Observed and expected rates shown are among cases with complete data. Regional data suppression is based on number of complete cases.

*** indicates region's observed rate differs significantly from its expected rate.
TCAR SYMP: Stroke/Death

Procedures performed between June 1, 2019 and May 31, 2020

Includes symptomatic admissions for TransCarotid Artery Revascularization (TCAR) only. Symptomatic admissions are admissions where the patient had an ipsilateral or contralateral retinal or cortical TIA or stroke within 180 days prior to surgery. Excludes any patient with prior vertebrobasilar TIA or stroke, prior ipsilateral CAS, CAS for intracranial treatment, or any procedure involving dissection, trauma, FMD, or “Other” lesion types. Procedures with an approach other than “Femoral” are also excluded.

The table below gives the number of TCAR procedures (performed on symptomatic admissions) meeting the inclusion criteria, and the observed and expected rates of in-hospital stroke or death for those cases.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of TCAR procedures meeting inclusion criteria</td>
<td>221</td>
<td>1803</td>
<td></td>
</tr>
<tr>
<td>Observed rate of stroke or death among procedures meeting inclusion criteria</td>
<td>1.4%</td>
<td>3%</td>
<td></td>
</tr>
<tr>
<td>Number of procedures with complete data*</td>
<td>215</td>
<td>1737</td>
<td></td>
</tr>
<tr>
<td>Observed rate of stroke or death among cases with complete data</td>
<td>1.4%</td>
<td>3.1%</td>
<td></td>
</tr>
<tr>
<td>Expected rate of stroke or death among cases with complete data*</td>
<td>2.7%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>P-value for comparison of observed and expected rates</td>
<td>0.39</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

*“Expected rate” is the rate estimated by a statistical model that accounts for patient characteristics, including age, gender, race, BMI, comorbidities, medication and stroke and vascular history. “Cases with complete data” include patients who have data on all of those factors.
Stroke or Death After TCAR for Symptomatic Admissions by Year

Rates shown are observed rates among cases meeting inclusion criteria.
Stroke or Death After TCAR for Symptomatic Admissions in Your Region (June 2019-May 2020)

Centers (centers with <10 complete cases not shown)

Observed and expected rates shown are among cases with complete data. Regional data suppression is based on number of complete cases.

"**" indicates center's observed rate differs significantly from its expected rate.

Stroke or Death After TCAR for Symptomatic Admissions by Region Across VQI (June 2019-May 2020)

Observed and expected rates shown are among cases with complete data. Regional data suppression is based on number of complete cases.

"**" indicates region's observed rate differs significantly from its expected rate.
CEA ASYMP: Stroke/Death

Procedures performed between June 1, 2019 and May 31, 2020

Includes asymptomatic admissions for Carotid Endarterectomy (CEA) only. Asymptomatic admissions are admissions where the patient had no ipsilateral retinal or cortical TIA or stroke within 180 days prior to surgery. Excludes any patient with prior vertebrobasilar or non-specific TIA or stroke, prior ipsilateral CEA or CAS, or any procedure with a concomitant CABG, proximal endovascular, distal endovascular, or “Other” arterial procedure.

The table below gives the number of CEA procedures (performed on asymptomatic admissions) meeting the inclusion criteria, and the observed and expected rates of in-hospital stroke or death for those cases.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of CEA procedures meeting inclusion criteria</td>
<td>1047</td>
<td>9499</td>
<td></td>
</tr>
<tr>
<td>Observed rate of stroke or death among procedures meeting inclusion criteria</td>
<td>0.5%</td>
<td>0.9%</td>
<td></td>
</tr>
<tr>
<td>Number of procedures with complete data*</td>
<td>997</td>
<td>9126</td>
<td></td>
</tr>
<tr>
<td>Observed rate of stroke or death among cases with complete data</td>
<td>0.5%</td>
<td>0.9%</td>
<td></td>
</tr>
<tr>
<td>Expected rate of stroke or death among cases with complete data*</td>
<td>0.9%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>P-value for comparison of observed and expected rates</td>
<td>0.24</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

*“Expected rate” is the rate estimated by a statistical model that accounts for patient characteristics, including age, gender, race, BMI, comorbidities, medication and stroke and vascular history. “Cases with complete data” include patients who have data on all of those factors.
Rates shown are observed rates among cases meeting inclusion criteria.
Stroke or Death After CEA for Asymptomatic Admissions in Your Region (June 2019-May 2020)

- Other centers in your region
- Your center
- Observed
- Expected

Centers (centers with <10 complete cases not shown)

Observed and expected rates shown are among cases with complete data. Regional data suppression is based on number of complete cases.

*** indicates center's observed rate differs significantly from its expected rate.

Stroke or Death After CEA for Asymptomatic Admissions by Region Across VQI (June 2019-May 2020)

Observed and expected rates shown are among cases with complete data. Regional data suppression is based on number of complete cases.

*** indicates region's observed rate differs significantly from its expected rate.
### CEA SYMP: Stroke/Death

Procedures performed between June 1, 2019 and May 31, 2020

Includes symptomatic admissions for Carotid Endarterectomy (CEA) only. Symptomatic admissions are admissions where the patient had an ipsilateral retinal or cortical TIA or stroke within 180 days prior to surgery. Excludes any patient with prior vertebrobasilar or non-specific TIA or stroke, prior ipsilateral CEA or CAS, or any procedure with a concomitant CABG, proximal endovascular, distal endovascular, or “Other” arterial procedure.

The table below gives the number of CEA procedures (performed on symptomatic admissions) meeting the inclusion criteria, and the observed and expected rates of in-hospital stroke or death for those cases.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of CEA procedures meeting inclusion criteria</td>
<td>353</td>
<td>4783</td>
<td></td>
</tr>
<tr>
<td>Observed rate of stroke or death among procedures meeting inclusion criteria</td>
<td>1.4%</td>
<td>1.7%</td>
<td></td>
</tr>
<tr>
<td>Number of procedures with complete data*</td>
<td>338</td>
<td>4612</td>
<td></td>
</tr>
<tr>
<td>Observed rate of stroke or death among cases with complete data</td>
<td>1.2%</td>
<td>1.6%</td>
<td></td>
</tr>
<tr>
<td>Expected rate of stroke or death among cases with complete data*</td>
<td>1.9%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>P-value for comparison of observed and expected rates</td>
<td>0.54</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

*“Expected rate” is the rate estimated by a statistical model that accounts for patient characteristics, including age, gender, race, BMI, comorbidities, medication and stroke and vascular history. “Cases with complete data” include patients who have data on all of those factors.
Stroke or Death After CEA for Symptomatic Admissions by Year

Rates shown are observed rates among cases meeting inclusion criteria.
Stroke or Death After CEA for Symptomatic Admissions in Your Region (June 2019-May 2020)

Centers (centers with <10 complete cases not shown)

Observed and expected rates shown are among cases with complete data. Regional data suppression is based on number of complete cases.

*** indicates centers observed rate differs significantly from its expected rate.

Stroke or Death After CEA for Symptomatic Admissions by Region Across VQI (June 2019-May 2020)

Regions (regions with <3 centers with at least 10 complete cases not shown)

Observed and expected rates shown are among cases with complete data. Regional data suppression is based on number of complete cases.

*** indicates region's observed rate differs significantly from its expected rate.
CEA ASYMPT: Postop LOS>1 Day

Procedures performed between June 1, 2019 and May 31, 2020

Includes asymptomatic admissions for Carotid Endarterectomy (CEA) only. Asymptomatic admissions are admissions where the patient had no ipsilateral retinal or cortical TIA or stroke within 180 days prior to surgery. Excludes any patient with prior vertebrobasilar or non-specific TIA or stroke, prior ipsilateral CEA or CAS, or any procedure with a concomitant CABG, proximal endovascular, distal endovascular, or "Other" arterial procedure. Procedures where in-hospital death occurred with postoperative LOS<=1 day are also excluded. Postoperative LOS is based on the midnight rule used for hospital billing.

The table below gives the number of CEA procedures (performed on asymptomatic admissions) meeting the inclusion criteria, and the observed and expected rates of postoperative LOS>1 Day for those cases.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of CEA procedures meeting inclusion criteria</td>
<td>1048</td>
<td>9498</td>
<td></td>
</tr>
<tr>
<td>Observed rate of LOS&gt;1 day among procedures meeting inclusion criteria</td>
<td>26.7%</td>
<td>23.3%</td>
<td></td>
</tr>
<tr>
<td>Number of procedures with complete data*</td>
<td>1003</td>
<td>9139</td>
<td></td>
</tr>
<tr>
<td>Observed rate of LOS&gt;1 day among cases with complete data</td>
<td>26.5%</td>
<td>23.1%</td>
<td></td>
</tr>
<tr>
<td>Expected rate of LOS&gt;1 day among cases with complete data*</td>
<td>23.9%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>P-value for comparison of observed and expected rates</td>
<td>0.05</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

*Expected rate* is the rate estimated by a statistical model that accounts for patient characteristics, including age, gender, race, BMI, comorbidities, medication and stroke and vascular history. *Cases with complete data* include patients who have data on all of those factors.
Postop LOS>1 Day after CEA for Asymptomatic Admissions by Year

Rates shown are observed rates among cases meeting inclusion criteria.
Observed and expected rates shown are among cases with complete data. Regional data suppression is based on number of complete cases.

"***" indicates center’s observed rate differs significantly from its expected rate.

Observed and expected rates shown are among cases with complete data. Regional data suppression is based on number of complete cases.

"***" indicates region’s observed rate differs significantly from its expected rate.
CEA SYMP: Postop LOS>1 Day

Procedures performed between June 1, 2019 and May 31, 2020

Includes symptomatic admissions for Carotid Endarterectomy (CEA) only. Symptomatic admissions are admissions where the patient had an ipsilateral retinal or cortical TIA or stroke within 180 days prior to surgery. Excludes any patient with prior vertebrobasilar or non-specific TIA or stroke, prior ipsilateral CEA or CAS, or any procedure with a concomitant CABG, proximal endovascular, distal endovascular, or “Other” arterial procedure. Procedures where in-hospital death occurred with postoperative LOS<=1 day are also excluded. Postoperative LOS is based on the midnight rule used for hospital billing.

The table below gives the number of CEA procedures (performed on symptomatic admissions) meeting the inclusion criteria, and the observed and expected rates of postoperative LOS>1 Day for those cases.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of CEA procedures meeting inclusion criteria</td>
<td>354</td>
<td></td>
<td>4784</td>
</tr>
<tr>
<td>Observed rate of LOS&gt;1 day among procedures meeting inclusion criteria</td>
<td>47.7%</td>
<td>43%</td>
<td></td>
</tr>
<tr>
<td>Number of procedures with complete data*</td>
<td>341</td>
<td></td>
<td>4620</td>
</tr>
<tr>
<td>Observed rate of LOS&gt;1 day among cases with complete data</td>
<td>46.9%</td>
<td>42.7%</td>
<td></td>
</tr>
<tr>
<td>Expected rate of LOS&gt;1 day among cases with complete data*</td>
<td>44.5%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>P-value for comparison of observed and expected rates</td>
<td>0.38</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

*“Expected rate” is the rate estimated by a statistical model that accounts for patient characteristics, including age, gender, race, BMI, comorbidities, medication and stroke and vascular history. “Cases with complete data” include patients who have data on all of those factors.
Rates shown are observed rates among cases meeting inclusion criteria.
Postop LOS>1 Day after CEA for Symptomatic Admissions in Your Region (June 2019-May 2020)

- Other centers in your region
- Your center
- Observed
- Expected

Centers (centers with <10 complete cases not shown)

Observed and expected rates shown are among cases with complete data. Regional data suppression is based on number of complete cases.

** indicates center's observed rate differs significantly from its expected rate.

Postop LOS>1 Day after CEA for Symptomatic Admissions by Region Across VQI (June 2019-May 2020)

- Observed
- Expected

Regions (regions with <3 centers with at least 10 cases complete not shown)

Observed and expected rates shown are among cases with complete data. Regional data suppression is based on number of complete cases.

** indicates region's observed rate differs significantly from its expected rate.
EVAR: Postop LOS>2 Days

Procedures performed between June 1, 2019 and May 31, 2020

Includes Endovascular AAA Repair (EVAR) procedures only. Excludes any procedure with ruptured aneurysm, patients with prior aortic surgery, or patients transferred from another hospital. Procedures where in-hospital death occurred with postoperative LOS≤2 are also excluded. Postoperative LOS is based on the midnight rule used for hospital billing.

The table below gives the number of EVAR procedures meeting the inclusion criteria, and the observed and expected rates of postoperative LOS>2 Days for those cases.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of EVAR procedures meeting inclusion criteria</td>
<td>394</td>
<td>5664</td>
<td></td>
</tr>
<tr>
<td>Observed rate of LOS&gt;2 days among procedures meeting inclusion criteria</td>
<td>18.8%</td>
<td>14.2%</td>
<td></td>
</tr>
<tr>
<td>Number of procedures with complete data*</td>
<td>349</td>
<td>5150</td>
<td></td>
</tr>
<tr>
<td>Observed rate of LOS&gt;2 days among cases with complete data</td>
<td>18.1%</td>
<td>14.1%</td>
<td></td>
</tr>
<tr>
<td>Expected rate of LOS&gt;2 days among cases with complete data*</td>
<td>14.6%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>P-value for comparison of observed and expected rates</td>
<td>0.07</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

*“Expected rate” is the rate estimated by a statistical model that accounts for patient characteristics, including age, gender, race, BMI, comorbidities, medication and stroke and vascular history. “Cases with complete data” include patients who have data on all of those factors.
Postop LOS >2 Days after EVAR by Year

Rates shown are observed rates among cases meeting inclusion criteria.
Observed and expected rates shown are among cases with complete data. Regional data suppression is based on number of complete cases.

*** indicates center’s observed rate differs significantly from its expected rate.

Observed and expected rates shown are among cases with complete data. Regional data suppression is based on number of complete cases.

*** indicates region’s observed rate differs significantly from its expected rate.
EVAR: Sac Diameter Reporting

Procedures performed between July 1, 2017 and June 30, 2018

Includes Endovascular AAA Repair (EVAR) procedures only. Excludes patients who were converted to open or died within 21 months of surgery.

The table below gives the number of EVAR procedures meeting the inclusion criteria, and the percentage of those procedures where a sac diameter was reported between 9 and 21 months post-procedure.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of EVAR procedures meeting inclusion criteria</td>
<td>478</td>
<td>6821</td>
<td></td>
</tr>
<tr>
<td>Percentage with sac diameter reported between 9 and 21 months post-procedure</td>
<td>53.6%</td>
<td>58.6%</td>
<td></td>
</tr>
</tbody>
</table>
**EVAR Sac Diameter Reporting in Your Region** (July 2017–June 2018)

- Other centers in your region
- Your center

**Centers (centers with <10 cases not shown)**

*** indicates center's observed rate differs significantly from its expected rate.

**EVAR Sac Diameter Reporting by Region Across VQI** (July 2017–June 2018)

- MidSouth*
- So. Cal*
- Michigan*
- New York*
- SoVONet*
- Pacific NW*
- Southeast
- Rocky Mtns.
- Virginias
- VQI
- Nor. Cal.
- Mid-Atlantic
- Carolinas*
- Midwest*
- Mid-America*
- New England*
- G. Lakes*
- Up. Midwest*
- Canada*

Regions (regions with <3 centers with at least 10 cases not shown)

*** indicates region's rate differs significantly from the VQI rate.
**EVAR: SVS Sac Size Guideline**

Procedures performed between June 1, 2019 and May 31, 2020

Includes Endovascular AAA Repair (EVAR) procedures only. Excludes any non-elective procedure. SVS sac size guideline is ≥5 cm for Women and ≥5.5cm for men. If the patient has any iliac aneurysm, the guideline is considered met regardless of AAA diameter.

The table below gives the number of EVAR procedures meeting the inclusion criteria, and the percentage of those procedures meeting the SVS sac size guideline.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of EVAR procedures meeting inclusion criteria</td>
<td></td>
<td>380</td>
<td>5426</td>
</tr>
<tr>
<td>Percentage meeting SVS sac size guideline</td>
<td></td>
<td>71.3%</td>
<td>73.4%</td>
</tr>
</tbody>
</table>
**EVAR Sac Size Guideline in Your Region (June 2019-May 2020)**

- **Other centers in your region**
- **Your center**

Centers (centers with <10 cases not shown)

**** Indicates center’s observed rate differs significantly from its expected rate.

---

**EVAR Sac Size Guideline by Region Across VQI (June 2019-May 2020)**

Regions (regions with <3 centers with at least 10 cases not shown)

**** Indicates region’s rate differs significantly from the VQI rate.
TEVAR: Sac Diameter Reporting

Procedures performed between July 1, 2017 and June 30, 2018

Includes Thoracic Endovascular Aortic Repair (TEVAR) procedures for aneurysm or aneurysm from dissection only. Excludes patients who were converted to open or died within 21 months of surgery.

The table below gives the number of TEVAR procedures meeting the inclusion criteria, and the percentage of those procedures where a sac diameter was reported between 9 and 21 months post-procedure.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of TEVAR procedures meeting inclusion criteria</td>
<td>139</td>
<td>1377</td>
<td></td>
</tr>
<tr>
<td>Percentage with sac diameter reported between 9 and 21 months post-procedure</td>
<td>51.8%</td>
<td>56.7%</td>
<td></td>
</tr>
</tbody>
</table>
TEVAR Sac Diameter Reporting in Your Region (July 2017–June 2018)

- Other centers in your region
- Your center

Centers (centers with <10 cases not shown)

Indicates center’s observed rate differs significantly from its expected rate.

TEVAR Sac Diameter Reporting by Region Across VQI (July 2017–June 2018)

Regions (regions with <3 centers with at least 10 cases not shown)

Indicates region’s rate differs significantly from the VQI rate.
OAAA: In-Hospital Mortality

Procedures performed between June 1, 2019 and May 31, 2020

Includes Open AAA (OAAA) procedures only. Excludes any patient with a ruptured aneurysm.

The table below gives the number of OAAA procedures meeting the inclusion criteria, and the observed and expected rates of in-hospital death for those cases.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of OAAA procedures meeting inclusion criteria</td>
<td>81</td>
<td>970</td>
<td></td>
</tr>
<tr>
<td>Observed rate of in-hospital death among procedures meeting inclusion criteria</td>
<td>3.7%</td>
<td>4.2%</td>
<td></td>
</tr>
<tr>
<td>Number of procedures with complete data*</td>
<td>72</td>
<td>916</td>
<td></td>
</tr>
<tr>
<td>Observed rate of in-hospital death among cases with complete data</td>
<td>4.2%</td>
<td>4.3%</td>
<td></td>
</tr>
<tr>
<td>Expected rate of in-hospital death among cases with complete data*</td>
<td>5.1%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>P-value for comparison of observed and expected rates</td>
<td>1</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Observed rate of in-hospital death among procedures with infrarenal proximal clamp</td>
<td>5.9%</td>
<td>2.9%</td>
<td></td>
</tr>
<tr>
<td>Observed rate of in-hospital death among procedures with suprarenal proximal clamp</td>
<td>2.3%</td>
<td>5.7%</td>
<td></td>
</tr>
</tbody>
</table>

*"Expected rate" is the rate estimated by a statistical model that accounts for patient characteristics, including age, gender, race, BMI, comorbidities, medication and stroke and vascular history. “Cases with complete data” include patients who have data on all of those factors.
Rates shown are observed rates among cases meeting inclusion criteria.
Observed and expected rates shown are among cases with complete data. Regional data suppression is based on number of complete cases. 

"***" indicates center’s observed rate differs significantly from its expected rate.

Observed and expected rates shown are among cases with complete data. Regional data suppression is based on number of complete cases. 

"***" indicates region’s observed rate differs significantly from its expected rate.
OAAA: SVS Cell-Saver Guideline

Procedures performed between June 1, 2019 and May 31, 2020

Includes Open AAA (OAAA) procedures only. Excludes any patient with EBL ≤ 500 ml. SVS cell-saver guideline is met if cell salvage or ultrafiltration device was used.

The table below gives the number of OAAA procedures meeting the inclusion criteria, and the percentage of those procedures meeting the SVS cell-saver guideline.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of OAAA procedures meeting inclusion criteria</td>
<td>79</td>
<td>1005</td>
<td></td>
</tr>
<tr>
<td>Percentage meeting SVS cell-saver guideline</td>
<td>97.5%</td>
<td>93.3%</td>
<td></td>
</tr>
</tbody>
</table>
OAAA Cell-Saver Guideline by Year

- Your Center
- Your Region
- VQI Overall
OAAA Cell-Saver Guideline in Your Region (June 2019-May 2020)

Centers (centers with <10 cases not shown)

"***" indicates center’s observed rate differs significantly from its expected rate

OAAA Cell-Saver Guideline by Region Across VQI (June 2019-May 2020)

Regions (regions with <3 centers with at least 10 cases not shown)

"***" indicates region’s rate differs significantly from the VQI rate.
OAAA: SVS Iliac Inflow Guideline

Procedures performed between June 1, 2019 and May 31, 2020

Includes Open AAA (OAAA) procedures only. SVS iliac inflow guideline is met if preservation of flow was maintained to at least one internal iliac artery.

The table below gives the number of OAAA procedures meeting the inclusion criteria, and the percentage of those procedures meeting the SVS iliac inflow guideline.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of OAAA procedures meeting inclusion criteria</td>
<td></td>
<td>94</td>
<td>1126</td>
</tr>
<tr>
<td>Percentage meeting SVS iliac inflow guideline</td>
<td></td>
<td>95.7%</td>
<td>98.6%</td>
</tr>
</tbody>
</table>
OAAA Iliac Inflow Guideline in Your Region (June 2019-May 2020)

- Other centers in your region
- Your center

**Centers (centers with <10 cases not shown)**

*** Indicates center's observed rate differs significantly from its expected rate

OAAA Iliac Inflow Guideline by Region Across VQI (June 2019-May 2020)

- Southeast
- VQI
- Mid-Atlantic
- Canada
- G. Lakes
- Michigan
- New England

Regions (regions with <3 centers with at least 10 cases not shown)

*** Indicates region's rate differs significantly from the VQI rate.
PVI: ABI/Toe Pressure

Procedures performed between June 1, 2019 and May 31, 2020

Includes Peripheral Vascular Intervention (PVI) procedures for claudication only. “ABI/Toe Pressure Assessment” indicates at least one ABI or toe pressure assessment was made prior to PVI for the side of the procedure, or on both sides for bilateral and aortic procedures.

The table below gives the number of PVI procedures meeting the inclusion criteria, and the percentage of those procedures in which an ABI or toe pressure was assessed prior to PVI.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of PVI procedures meeting inclusion criteria</td>
<td>1166</td>
<td>13412</td>
<td></td>
</tr>
<tr>
<td>Percentage with ABI/toe pressure assessment</td>
<td>46.9%</td>
<td>74.6%</td>
<td></td>
</tr>
<tr>
<td>Percentage who were current smokers</td>
<td>34.4%</td>
<td>36.5%</td>
<td></td>
</tr>
</tbody>
</table>
ABI/Toe Pressure Assessment Before PVI in Your Region (June 2019-May 2020)

Other centers in your region  Your center

Centers (centers with ≤10 cases not shown)

*** Indicates center’s observed rate differs significantly from its expected rate.

ABI/Toe Pressure Assessment Before PVI by Region Across VQI (June 2019-May 2020)

Regions (regions with ≤3 centers with at least 10 cases not shown)

*** Indicates region’s rate differs significantly from the VQI rate.
INFRA: Major Complications

Procedures performed between June 1, 2019 and May 31, 2020

Includes Infrainguinal Bypass (INFRA) procedures only. Excludes any patient with an indication other than rest pain or tissue loss. Major complications are defined as in-hospital death, ipsilateral BK or AK amputation, or graft occlusion.

The table below gives the number of INFRA procedures meeting the inclusion criteria, and the percentage of those procedures that resulted in in-hospital death, ipsilateral BK or AK amputation, or graft occlusion.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of INFRA procedures meeting inclusion criteria</td>
<td>283</td>
<td>4119</td>
<td></td>
</tr>
<tr>
<td>Percentage with major complications</td>
<td>3.5%</td>
<td>4.1%</td>
<td></td>
</tr>
</tbody>
</table>
Major Complications After INFRA in Your Region (June 2019-May 2020)

- **Other centers in your region**
- **Your center**

Centers (centers with <10 cases not shown)

*** Indicates center's observed rate differs significantly from its expected rate.

Major Complications After INFRA by Region Across VQI (June 2019-May 2020)

Regions (regions with <3 centers with at least 10 cases not shown)

*** Indicates region's rate differs significantly from the VQI rate.
SUPRA: Major Complications

Procedures performed between June 1, 2019 and May 31, 2020

Includes Suprainguinal Bypass (SUPRA) procedures only. Excludes any patient with an indication other than rest pain or tissue loss. Major complications are defined as in-hospital death, ipsilateral BK or AK amputation, or graft occlusion.

The table below shows the number of SUPRA procedures meeting the inclusion criteria, and the percentage of those procedures that resulted in in-hospital death, ipsilateral BK or AK amputation, or graft occlusion.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of SUPRA procedures meeting inclusion criteria</td>
<td></td>
<td>92</td>
<td>841</td>
</tr>
<tr>
<td>Percentage with major complications</td>
<td></td>
<td>3.3%</td>
<td>5.2%</td>
</tr>
</tbody>
</table>
Major Complications After SUPRA in Your Region (June 2019-May 2020)

- Other centers in your region
- Your center

Centers (centers with <10 cases not shown)

"***" indicates center’s observed rate differs significantly from its expected rate

Major Complications After SUPRA by Region Across VQI (June 2019-May 2020)

- Carolinas
- Southeast
- New England
- G. Lakes
- VQI

Regions (regions with <3 centers with at least 10 cases not shown)

"***" indicates region’s rate differs significantly from the VQI rate.
LEAMP: Postop Complications

Procedures performed between June 1, 2019 and May 31, 2020

Includes Lower-Extremity Amputation (LEAMP) procedures only. Postoperative complications are defined as myocardial infarction, dysrhythmia, congestive heart failure, surgical site infection, renal complication, or respiratory complication.

The table below gives the number of LEAMP procedures meeting the inclusion criteria, and the percentage of those procedures that resulted in a postoperative complication.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of LEAMP procedures meeting inclusion criteria</td>
<td></td>
<td>304</td>
<td>3062</td>
</tr>
<tr>
<td>Percentage with postoperative complications</td>
<td></td>
<td>7.6%</td>
<td>12%</td>
</tr>
</tbody>
</table>
Postop Complications After LEAMP by Year

- Your Center
- Your Region
- VQI Overall
Postop Complications After LEAMP in Your Region (June 2019-May 2020)

Centers (centers with <10 cases not shown)

*** indicates center's rate differs significantly from the regional rate.

Postop Complications After LEAMP by Region Across VQI (June 2019-May 2020)

Regions (regions with <3 centers with at least 10 cases not shown)

*** indicates region's rate differs significantly from the VQI rate.
**AVACCESS: Primary AVF vs. Graft**

Procedures performed between June 1, 2019 and May 31, 2020

Excludes procedures where Access Type = Endo AVF or patients with a previous access procedure in the same arm.

The table below gives the number of procedures meeting the inclusion criteria, and the percentage of those procedures that were primary AVF.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of AVACCESS procedures meeting inclusion criteria</td>
<td>428</td>
<td>5116</td>
<td></td>
</tr>
<tr>
<td>Percentage with primary AVF</td>
<td>68.9%</td>
<td>82.1%</td>
<td></td>
</tr>
</tbody>
</table>
Primary AVF Access in Your Region (June 2019-May 2020)

- Other centers in your region
- Your center

Centers (centers with <10 cases not shown)

*** Indicates center’s rate differs significantly from the regional rate.

Primary AVF Access by Region Across VQI (June 2019-May 2020)

Regions (regions with <3 centers with at least 10 cases not shown)

**** Indicates region’s rate differs significantly from the VQI rate.
IVCF: Filter Retrieval Reporting

Procedures performed between January 1, 2019 and December 31, 2019

Excludes patients with permanent filters, patients who have died since discharge, or patients where no follow-up was possible.

The table below gives the number of procedures meeting the inclusion criteria, and the percentage of those procedures in which the filter was reported as retrieved (or retrieval was attempted) at any time post-procedure. Because follow-up is critical for assessing filter retrieval, cases meeting the inclusion criteria are broken down into those with follow-up records (at least 1 follow-up record) and those without follow-up records.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of IVCF procedures meeting inclusion criteria</td>
<td>110</td>
<td>1427</td>
<td></td>
</tr>
<tr>
<td>Number without follow-up records</td>
<td>91</td>
<td>1023</td>
<td></td>
</tr>
<tr>
<td>Number with follow-up records</td>
<td>19</td>
<td>404</td>
<td></td>
</tr>
<tr>
<td>Percentage with Filter Retrieval, or Attempt at Retrieval</td>
<td>9.1%</td>
<td>22.8%</td>
<td></td>
</tr>
<tr>
<td>Percentage not retrieved because No Follow-up Records Created</td>
<td>82.7%</td>
<td>71.7%</td>
<td></td>
</tr>
<tr>
<td>Percentage not retrieved because Not Clinically Indicated</td>
<td>6.4%</td>
<td>3.5%</td>
<td></td>
</tr>
<tr>
<td>Percentage not retrieved because Patient Declined</td>
<td>0.9%</td>
<td>0.8%</td>
<td></td>
</tr>
<tr>
<td>Percentage not retrieved because Lost to Follow-Up</td>
<td>0%</td>
<td>0.1%</td>
<td></td>
</tr>
<tr>
<td>Percentage not retrieved because Deemed Too Late for Removal</td>
<td>0%</td>
<td>0%</td>
<td></td>
</tr>
<tr>
<td>Percentage not retrieved because Planned Later Removal</td>
<td>0.9%</td>
<td>0.8%</td>
<td></td>
</tr>
<tr>
<td>Percentage not retrieved because No Reason Given</td>
<td>0%</td>
<td>0.3%</td>
<td></td>
</tr>
</tbody>
</table>
Filter Retrieval Reporting in Your Region (January-December 2019)

- Other centers in your region
- Your center

Centers (centers with <10 cases not shown)

"***" indicates center's rate differs significantly from the regional rate.

Filter Retrieval Reporting by Region Across VQI (January-December 2019)

Regions (regions with <3 centers with at least 10 cases not shown)

"***" indicates region's rate differs significantly from the VQI rate.
SEVSG LTFU QI Project: Kathie Shemwell/Michelle Glanville

• Regional data manager kick off meeting held 8/12/2020

• Discussed charter development

• Encouraged data managers to participate with the following regional and individual site goals:
  – SEVSG goal: to improve current 62% to 50th percentile of 73% (based on 2017 procedures LTFU submissions) for the 2018 procedure LTFU
  – Participating sites at ≥ 90% strive to maintain
  – Participating sites at ≤ 60% strive to set goal at 73%
  – Participating sites between 73% - 88% strive to ↑between 3 to 5% above 2017 performance

• Dropped from 62% to 56% with fall report

• Any one want to disclose if participating in this initiative
National VQI Update:
Caroline Morgan, SVS PSO
Number of Participating Centers

Location of VQI Participating Centers

693 VQI Centers
692 centers in North America
1 center in Singapore
### Total Procedures Captured (as of 8/1/2020)

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peripheral Vascular Intervention</td>
<td>238,942</td>
</tr>
<tr>
<td>Carotid Endarterectomy</td>
<td>143,322</td>
</tr>
<tr>
<td>Infra-Inguinal Bypass</td>
<td>62,429</td>
</tr>
<tr>
<td>Endovascular AAA Repair</td>
<td>57,846</td>
</tr>
<tr>
<td>Hemodialysis Access</td>
<td>57,648</td>
</tr>
<tr>
<td>Carotid Artery Stent</td>
<td>44,584</td>
</tr>
<tr>
<td>Varicose Vein</td>
<td>40,050</td>
</tr>
<tr>
<td>Supra-Inguinal Bypass</td>
<td>20,437</td>
</tr>
<tr>
<td>Thoracic and Complex EVAR</td>
<td>18,718</td>
</tr>
<tr>
<td>Lower Extremity Amputations</td>
<td>18,595</td>
</tr>
<tr>
<td>IVC Filter</td>
<td>14,549</td>
</tr>
<tr>
<td>Open AAA Repair</td>
<td>13,918</td>
</tr>
</tbody>
</table>

**Total Procedure Volume**

Total Procedure Volume tab reflects net procedures added to the registry for the month.
VQI OnLine Highlights:

- VQI OnLine hosted 12 sessions over 6 weeks
- Attendance ranged from 300 – 125 live users
- PSO thanks all the Speakers and Moderators
- Feedback has largely been positive.
- Need a better registration and invite process
- Will incorporate virtual sessions even as we return to a live event
- Replays can be found on the VQI Members Only website.
After the successful completion of our first VQI ONLINE event series, we have posted the video content on the Members Only area.

If you wish to view any of the video sessions, please log in to the VQI Members Only area on the website. (If you do not have credentials for Members Only, please contact Nancy Heatley to set up your access. This is only available for registered VQI members.)

VQI Members Only – [https://www.vqi.org/members-login/](https://www.vqi.org/members-login/)

Full recordings of each event are available at no cost to VQI members through Members Only.

Contact Nancy Heatley [Nheatley@svspso.org](mailto:Nheatley@svspso.org) if you need assistance!
ACC, SVS Join Forces on Single Vascular Registry

The American College of Cardiology and Society for Vascular Surgery are collaborating on a single vascular registry to harness the strengths of both organizations in improving care and outcomes of patients with vascular disease.

https://www.vqi.org/acc-svs-join-forces-on-single-vascular-registry/
Vascular Medicine Consult Registry

Collaboration:

Society for Vascular Surgery
American Heart Association
Society for Vascular Medicine
**Inclusion Criteria:**
This registry only includes New Outpatient Consults who are being treated *medically* for:

- Lower Extremity peripheral arterial disease due to atherosclerosis
- Atherosclerotic carotid artery occlusive disease
- Abdominal aortic aneurysm

**Exclusion Criteria:**

- Evaluation/diagnosis of pseudo or neurogenic claudication, peripheral arterial disease due to trauma, popliteal entrapment, medial adventitious cystic disease, chronic compartment syndrome
- Carotid disease due to dissection, infection, aneurysm, tumor, isolated common carotid lesion not thought to involve the bifurcation, disease of the carotid bifurcation due solely to vasculitis, and Moyamoya disease, and fibromuscular dysplasia
- Isolated aortic dissection without aneurysm
- Thoracic, thoraco-abdominal, and mycotic aneurysms
Vascular Medicine Consult Registry

• **Data Collection:**
  – Registry to focus on non-operative medical management of these conditions
  – Medication details and dosages, along with lifestyle modifications and counseling will be the emphasis of this registry

• **Opportunities**
  – Identify patterns/variation of treatment and pre-intervention management
  – Identify QI initiatives
  – Opportunities in comparative effectiveness research
First site signed and entering data! Many more in the contracting phase!


Recorded webinars: https://www.vqi.org/vascular-medicine-consult-registry-webinar-recordings-available/

For more information please contact:
  – VQI@M2S.com
## COVID-19 Variables:

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Description</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procedure</td>
<td>COVID status at time of procedure</td>
<td>0=Unknown, not tested; 1=Tested negative pre-op; 2=Tested positive pre-op; 3=Tested negative pre-op but positive post-op</td>
</tr>
<tr>
<td>Procedure</td>
<td>COVID symptoms pre-procedure</td>
<td>1=Asymptomatic, 2=Symptomatic, not intubated, 3=Symptomatic, intubated</td>
</tr>
<tr>
<td>Procedure</td>
<td>Treatment delay by pandemic</td>
<td>0=None, 1=Delayed &lt; 2 weeks, 2=Delayed 2-6 weeks, 3=Delayed &gt; 6 weeks, 4=Uncertain</td>
</tr>
<tr>
<td>Procedure</td>
<td>Impact of delay in treatment</td>
<td>0=No, impact in tx due to delay, 1=Yes, impact of tx due to delay 2=Indeterminate</td>
</tr>
<tr>
<td>30 day and LTFU</td>
<td>COVID Test Status after D/C</td>
<td>0= Never tested, no symptoms, 1= Never tested, but had symptoms, 2= Interval test positive with no current symptoms, 3= Interval test positive with active symptoms, 4= Interval test negative with no current symptoms, 5= Interval test negative with active symptoms,</td>
</tr>
</tbody>
</table>
COVID-19 Variable Roll out:

<table>
<thead>
<tr>
<th>Release Date</th>
<th>Registry</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Friday, August 28, 2020</strong></td>
<td>Open AAA Repair</td>
</tr>
<tr>
<td></td>
<td>Carotid Endarterectomy (CEA)</td>
</tr>
<tr>
<td><strong>Saturday, August 29, 2020</strong></td>
<td>Supra-inguinal Bypass (Supra)</td>
</tr>
<tr>
<td></td>
<td>Infra-inguinal Bypass (Infra)</td>
</tr>
<tr>
<td></td>
<td>Hemodialysis Access (HDA)</td>
</tr>
<tr>
<td></td>
<td>Varicose Vein (VV) *COVID variables only</td>
</tr>
<tr>
<td></td>
<td>Venous Stent (VSR)</td>
</tr>
<tr>
<td></td>
<td>Peripheral Vascular Intervention (PVI)</td>
</tr>
<tr>
<td><strong>Late September 2020 - to be announced</strong></td>
<td>Carotid Artery Stent (CAS)</td>
</tr>
<tr>
<td></td>
<td>IVC Filter (IVC)</td>
</tr>
<tr>
<td></td>
<td>Lower Extremity Amputation (LEA)</td>
</tr>
<tr>
<td></td>
<td>Endo AAA Repair (EVAR)</td>
</tr>
<tr>
<td></td>
<td>Thoracic and Complex EVAR (TEVAR)</td>
</tr>
</tbody>
</table>

**Other COVID-19 Info**

We are aware that COVID-19 has put a significant strain on staff and resources. The SVS PSO VQI will do our best to assure that any temporary workflow disruption will not have a negative impact on SVS VQI work or subsequent participation awards.
My Peripheral Arterial Disease: a VQI Pilot of Patient Reported Outcomes for PAD

- The Society for Vascular Surgery Vascular Quality Initiative is seeking practices to participate in My PAD, a pilot program for the collection of patient reported outcomes (PRO) on patients undergoing endovascular treatment for peripheral arterial disease (PAD).
- The VQI recognizes that traditional outcomes such as patency and reintervention may not fully capture the quality of care or the experience of PAD patients. There is a long overdue need to learn and measure the patient’s perspective.
- Must be in the PVI registry and have greater than 80% follow up!
**Highlights**

- Outpatient peripheral vascular interventions (PVI) for claudication or chronic limb threatening ischemia
- Collect VascuQoL-6 and EuroQoL 5D-5L (estimated completion time 10-15 minutes)
- Collection at three time points: pre-procedure, one month and one year postoperatively
- PRO data entry options include paper forms, computer, tablet and smart phone
- Educational materials for direct from patient data entry
- PRO feedback to participating physicians
Reporting Highlights and Questions:

• Changes to Perioperative Dashboards
• New On-line LTFU reports
• Suggestions for “other reports”? 

117
Perioperative Dashboard Remodel
Overall Modifications

Change explanation language- confusing

- Note also that percentages are computed only among cases with non-missing data for each outcome, so it is possible to have rates for some outcomes but “No cases” for others.
- Better to say??: Only cases with complete data have been analyzed.

Reorder sequence

- Combine CAS and CEA under “All carotid interventions”- give % of type
- All Carotid; then all Aortic (TEVAR/EVAR/OAAA/Supra); then all LE (PVI/LEB/Amp); then all Vein (VV/IVC/AVF); then Medical

Eliminate null entry of registry data

- Inefficient and visual fatigue- leave blank and provide no entry; should not require major reprogramming

Develop common metric for complications

- Return to OR (RTOR) should be common to all with ‘BTR’: bleeding/thrombosis/revision and then use registry specific complications in separate row or with BTR

Provide One year and 3 year comparators

- Since Dashboard is quarterly, a rapid look at 1Y and 3Y trend data will be very useful and can be provided via linkage

Include Category under each registry of excluded ‘N’s
Items to consider changing on current dashboards

- Reorganize sequence:
  Carotid ➔ Aortic ➔ LE ➔ Vein ➔ Medical

- Rolling quarter concept to allow for statistical merit on low volume procedures such as OAAA, etc. to achieve N > ~ 15. This would also be carried over to LTFU regional reports comparison

- Add LTFU metric to category dashboard ➔ Hyperlink option

- Replace 25\textsuperscript{th} / 50\textsuperscript{th} / 75\textsuperscript{th} percentile with whiskerplot: 90-10\%tile which shows median of VQI and arrow locating center level \%tile
• Combine into all carotid interventions for total of procedures in center
• Asymptomatic definition changed to 180 days
• Breakout into % CAS vs CEA as well as %TCAR vs TFCAS
• Under each category above: % Age >/= 80 and % CMS High Risk Criteria
• MACE reported separated for Total CAS (TCAR + TFCAS) and CEA
• Contralat/Ipsi CVA reported for each procedure type
• List BTR separately from Cranial Nerve Injury
• % Protamine reversal included in CEA report
• Continue with ‘Case data’; ‘DC meds’; ‘Discharge’; ‘IV meds for BP’ and Dysrhythmia treatment
• **Combined totals** used when statistics do not support separating outcomes and in ‘Home’ disposition
• Homeless and other hospital eliminated from Disposition
Interventions include all carotid procedures meeting entry criteria for CAS and CEA registries with separation of Asymptomatic and Symptomatic presentation.

Asymptomatic patients are those who had no ipsilateral or contralateral TIA or stroke within 180 days prior to surgery.

Total Carotid Interventions N = 130  CAS 68 (52%) with TCAR 64 (49%)/ CEA 62(48%)

<table>
<thead>
<tr>
<th>Category</th>
<th>Outcome/Complication</th>
<th>Asymptomatic N =100 %CAS/CEA</th>
<th>Symptomatic N =30 %CAS/CEA</th>
<th>Region N % CAS/CEA</th>
<th>National N % CAS/CEA</th>
</tr>
</thead>
<tbody>
<tr>
<td>DC Meds</td>
<td>Antiplatelet + Statin</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>MACE</td>
<td>%Mortality</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>%CVA</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>%MI</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>% CHF</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>Disposition</td>
<td>Home</td>
<td>Combined total</td>
<td>Combined total</td>
<td>Combined total</td>
<td>Combined total</td>
</tr>
<tr>
<td>Total Carots</td>
<td>Home</td>
<td>Combined total</td>
<td>Combined total</td>
<td>Combined total</td>
<td>Combined total</td>
</tr>
<tr>
<td>Rehab Unit/Nursing Home</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
</tbody>
</table>
Interventions include all carotid procedures meeting entry criteria for CAS and CEA registries with separation of Asymptomatic and Symptomatic presentation. Asymptomatic patients are those who had no ipsilateral or contralateral TIA or stroke within 180 days prior to surgery.

<table>
<thead>
<tr>
<th>Category</th>
<th>Outcome/Complication</th>
<th>Asymptomatic N = 45</th>
<th>Symptomatic N = 19</th>
<th>Region N</th>
<th>National N</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAS N = 68</td>
<td>TCAR N= 64 TFCAS N = 4</td>
<td>Combined total</td>
<td>Combined total</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Median PLOS</td>
<td>Combined total</td>
<td>Combined total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RTOR</td>
<td>(Bleeding/Thrombosis/Revision)</td>
<td>Combined total</td>
<td>Combined total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CVA %TFCAS</td>
<td>% Contralateral/Ipsilateral</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>CVA % TCAR</td>
<td>% Contralateral/Ipsilateral</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>Age</td>
<td>Number patients &gt;/= 80</td>
<td>Combined total</td>
<td>Combined total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Med use</td>
<td>(IV meds for DysR → Rx or Hyper/Hypotension)</td>
<td>Combined total</td>
<td>Combined total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High Risk</td>
<td>(% meeting CMS criteria)</td>
<td>Combined total</td>
<td>Combined total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CN Injury</td>
<td>(% X/XII injury at discharge)</td>
<td>Combined total</td>
<td>Combined total</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Carotid Endarterectomy**

Asymptomatic patients are those who had no ipsilateral or contralateral TIA or stroke within 180 days prior to surgery.

Interventions include all carotid procedures meeting entry criteria for CAS and CEA registries with separation of Asymptomatic and Symptomatic presentation.

<table>
<thead>
<tr>
<th>Category</th>
<th>Outcome/Complication</th>
<th>Asymptomatic N = 50</th>
<th>Symptomatic N = 12</th>
<th>Region N</th>
<th>National N</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEA N=62</td>
<td>Numbers of cases reviewed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Median PLOS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RTOR</td>
<td>(Bleeding/Thrombosis/Revision)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CVA</td>
<td>% Contralateral/ipsilateral</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>Age</td>
<td>Number patients &gt;/= 80</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Med use</td>
<td>(IV meds for DysR→Rx or Hyper/Hypotension)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protamine</td>
<td>% with reversal of anticoag</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High Risk</td>
<td>(% meeting CMS criteria)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CN Injury</td>
<td>(% X/XII injury at discharge)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
New On-Line LTFU Reports
• Select sites scheduled to test Mid October 2020
• To be rolled out to all sites soon
• Over time LTFU reports to be created for all registries (CEA/CAS next)
• *A toggle will be provided at the top of the report to show or hide the (n/m) values
• Ability to drill down to the patient PRIMPROCID
• Ability to filter on Elective, Ruptured, Symptomatic

<p>| My Center (Patients = xx) (Cases = xx) | My Region (Patients = xx) (Cases = xx) | Percentile | All VQI (Patients = xx) (Cases = xx) | Percentile |</p>
<table>
<thead>
<tr>
<th>Follow-up</th>
<th>My Center (Patients = xx) (Cases = xx)</th>
<th>My Region (Patients = xx) (Cases = xx)</th>
<th>Percentile</th>
<th>All VQI (Patients = xx) (Cases = xx)</th>
<th>Percentile</th>
</tr>
</thead>
<tbody>
<tr>
<td>Follow-up</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td></td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td></td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Frequent</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Cases with LTFU &gt;= 9 months</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Freedom from Death (1yr K/M)</td>
<td>XX.x% ± X.x%</td>
<td>XX.x% ± X.x%</td>
<td>XX</td>
<td>XX.x% ± X.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Status at most recent follow-up</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Living Status</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Home</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Homeless</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Nursing Home</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>New nursing home</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Functional Status</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Full</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Light Work</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Self-care</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Assisted Care</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Bed Bound</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Worse Function</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prior</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Current</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Never</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Quit since procedure</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Started since procedure</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Renal Function</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New onset dialysis</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Creatinine increase &gt; 0.5 mg/dl</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Medication</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiplatelet</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Statin</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Anticoagulant</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
</tbody>
</table>
### Imaging at most recent follow-up

<table>
<thead>
<tr>
<th>Patients having no f/u</th>
<th>XX.x%</th>
<th>XX.x%</th>
<th>XX</th>
<th>XX.x%</th>
<th>XX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Among Patients having f/u</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>CT/CTA</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Duplex</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>MR/MRA</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Angio</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Plain Film</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Max AAA Diameter</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shrinkage &gt;= 5 mm</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>No change &gt;= 5 mm</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Expansion &gt;= 5 mm</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
</tbody>
</table>

### Complications

<table>
<thead>
<tr>
<th>Access Site</th>
<th>XX.x%</th>
<th>XX.x%</th>
<th>XX</th>
<th>XX.x%</th>
<th>XX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infection</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Pseudoaneurysm</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Stenosis</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Occlusion</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Access Complication Treatment Required</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Medical</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Interventional</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Surgical</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Graft Limb Occlusions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Unilateral</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Bilateral</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Renal Artery Encroachment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Stenosis</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Occlusion</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Endoleak, current</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Type Ia</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Type Ib</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Type II</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Type IIIa</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Type IIIb</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Indeterminate</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Endoleak, any time since treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Type Ia</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Type Ib</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Type II</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Type IIIa</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Type IIIb</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
<tr>
<td>Indeterminate</td>
<td>XX.x%</td>
<td>XX.x%</td>
<td>XX</td>
<td>XX.x%</td>
<td>XX</td>
</tr>
</tbody>
</table>
Report Suggestions/Ideas?
Quorum:

- All voting for nominations and election of officers will be conducted electronically, even during in-person regional meetings. In order to conduct business, a quorum of the regional Executive Committee (EC) is considered a majority vote of all regional members of the EC that participate in the voting process. Centers are eligible to vote as of the date of the signed contract. No waiting period is required. The regional EC is entitled to one vote per center.

- An email notification to the region will be forwarded one week prior to the opening of officer nominations. A region will be permitted a collection period of one week to nominate individuals for the respective office and subsequently the regional EC will be given three weeks to vote for their member of choice.

- A regional EC member may designate a proxy for the purposes of voting provided that the VQI is notified in writing, by replying to the voting communication, prior to the end of the voting period. For voting that takes place without SVS PSO involvement, the Regional Medical Director will manage and conduct the voting process in accordance with the regional Bylaws’ rules of voting, meeting a quorum. The Regional Medical Director will give prior notification to the regional EC, by means of an agenda, if a vote will be conducted during an upcoming EC meeting or regional meeting.
Regional Bylaw Changes

Associate Medical Director:

- The Regional Associate Medical Director (AMD) is a VQI participating physician that will be nominated by the regional Executive Committee (EC) with a final vote based on the regional bylaw policies. This position will report directly to the Regional Medical Director. The Regional AMD will support the Regional Medical Director in managing the region with the application of regional guidelines. Tasks include, but are not limited to, assisting with agenda preparation, budgeting, regional meeting planning and the overall operations of the region. This role is a three-year renewable term, with an automatic succession into the Regional Medical Director’s role unless the SVS PSO receives written objection(s) from member(s) of the regional EC. A final vote of the regional EC is required to sanction the transition from Regional AMD to Regional Medical Director.
Medical Director Qualifications:

• The Medical Director is a VQI participating physician selected for a three-year renewable term by a majority vote, as defined in the regional Bylaws, of the Executive Committee (EC). The Regional Medical Director chairs the EC, prepares the agenda for meetings, prepares an annual budget and is responsible for the overall operations of the region between meetings of the EC. The Regional Medical Director will represent the region on the SVS PSO National Governing Council, unless the EC decides to elect someone else in the region.
CME/CE CREDIT FOR REGIONAL MEETINGS

FALL 2020
Des Moines University is the continuing education provider for this activity. This meeting will be awarded 2.0 AMA PRA Category 1 Credit™, AOA credit, and nursing contact hours.

Attendance has to be meticulously kept with professional role. The attendance roster will be cross-referenced with those applying for CME/CE.

Each participant **MUST COMPLETE BOTH** the attendance attestation and the meeting evaluation from the URL site – one form.

You will have 7 days from the date of the meeting to complete the forms and **SUBMIT**.

Approximately 14 days from the meeting, Des Moines University will email you instructions on how to access your certificate.

Continuing education credit is provided to you at no charge. Funding for this has been provided by the SVS PSO for the Fall 2020 meeting.

**One final note of caution:** if you do not complete the online forms and submit within 7 days, continuing education credit cannot be awarded.
So Again............You have 7 days!!

A message (see below) will be placed on the regional web page immediately following the regional meeting with a link to the application for credit:

For CME/CE credit, please click this link: https://dmu.co1.qualtrics.com/jfe/form/SV_dj3nVgjPUKzVORL

Complete both parts of the form and **Don’t Forget to hit SUBMIT** for credit!
Participation Award Changes

We are aware that COVID-19 placed a significant strain on staff and resources

- Formal announcement sent out April 9, 2020
- Personnel may have been reassigned making the performance of usual operations difficult if not impossible
- Many patients have had their follow-up office visits delayed. This may result in patients being seen outside of the prescribed time period (9-21 months) which is beyond anyone’s control.
- Workflow disruptions may have caused delays in data entry and follow-up

The Participation Committee will assess the 2020 Participation Award criteria to assure that temporary workflow disruptions will not have a negative impact on participation awards.

Updates will be provided via December QI webinar, newsletter, and email blast.
Quality Improvement Update

Fall 2020
Quality Improvement Webinars:

- 2020 Quarterly Webinars
  - March 2020
    - “Starting a QI project”
  - June 2020
    - Deferred for Online VQI
  - September 2020
    - Featuring Northern California Vascular Study Group and their processes for two regional projects
  - November/December 2020
    - 2020 Participation Award Information, 2021 Changes and Wrapping up a QI Project
2020 Quality Improvement

• Fourteen charters submitted
  – *LTFU – 5
  – D/C Medications – 4
  – Clinical – 2 (LOS – EVAR, LE)
  – **Documentation – 1 (AAA size compliance)

*2 regions finalizing details for LTFU QI project

** Multi-regional project - finalizing details for AAA size compliance QI project

• Focused phone calls are well attended
Recap of 2019/2020 QI Projects

Putting VQI Data into Action
See what your colleagues are doing with QI

• Twenty-eight poster abstracts were submitted and accepted for presentation at the 2020 VQI Annual meeting that was scheduled for Toronto
• Five abstracts were featured in the Online QI session
• Seven abstracts were featured in the Online RAC session

Great feedback received for all presentations!

Thanks to all who presented and attended the Online VQI sessions!
## Quality Improvement Details: Charter Information

<table>
<thead>
<tr>
<th></th>
<th>Activity</th>
<th>Documentation</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>QI Project Initiation</td>
<td>Attestation to include:</td>
<td>2 points</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• QI Project Title</td>
<td>Can be submitted at anytime</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Problem Statement</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Goal</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Scope</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Deliverables</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Resources needed</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Project Leader</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Clinical Sponsor</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Expected start/finish date</td>
<td></td>
</tr>
</tbody>
</table>

Form can be accessed at [https://www.vqi.org/vqi-resource-library/quality-improvement/](https://www.vqi.org/vqi-resource-library/quality-improvement/)

- Project charters should be emailed to QI@SVSPSO.ORG or cjackson@svpsso.org
Charters

- Charter participants become part of focused group calls
  - Interactive discussion sharing barriers and successes
  - Sharing of charters
  - Networking
  - Checking in – where are you in the process
  - Celebrating success

One on one calls, if requested
Newsletters

- **The VQI News**
  - Distributed every other month
  - Provides updates on regulatory issues, technical updates, and crossover news from the SVS and SVN

- **VQI Quality Improvement Newsletter**
  - Distributed every other month
  - Focusing on QI processes, tools, and definitions
National QI project details

• Submit Project Charters and supporting documentation for presentations and posters to QI@SVSPSO.ORG or cjackson@svspso.org.

• Visit the VQI Members Only Website for sample charters, webinars, and presentations on VQI Quality Improvement Projects. www.vqi.org
AQC Update: Adam Beck, MD

- Randy DeMartino, MD (Mayo Clinic Rochester) is the new Chair of the AQC
AQC Update:

• Current projects:
  – Common variable help text updates
  – OAAA registry revisions
  – SVS guidelines collaboration
  – COVID variables
  – Patient reported outcome variables
VQC Update: Olamide Alabi, MD

- Marc Passman, MD (UAB) new chair of the VQC taking over for Jose Almeida, MD
  - 1-3 year goals
    - Dedicated podium time for VQI at AVF
    - Update Varicose Vein and IVC quarterly interoperative dashboards
    - Create Venous Stent dashboard
    - Work on LTFU dashboards for all 3 venous procedures
    - Continue work C2 disease and appropriateness of care
    - Continue work with United Healthcare
    - IVC retrieval rate is 30% nationally, need to make this a national quality initiative
    - Create COPI (Center Opportunity for Process Improvement) reports for venous registries
Research Advisory Council
Emily Spangler, MD
Arterial Research Council

• June cycle 37 submissions
• August cycle 29 submissions

• 4 approved COVID projects to date
National Research Data Process

Upcoming National Arterial RAC Dates

**October 2020**
- Call for Proposals: August 11, 2020
- Due Date: September 28, 2020
- Meeting: October 12, 2020
- Notification Sent: October 16, 2020

**December 2020**
- Call for Proposals: October 13, 2020
- Due Date: November 30, 2020
- Meeting: December 14, 2020
- Notification Sent: December 18, 2020
• No Restriction of data release based on similar projects; collaboration is encouraged
• Only 1 refresh of data within 24 months of initial approval
• Industry related projects need to collaborate with the steering committee/s (i.e. TCAR)
  – Review policy and industry charters on the web
• Product Identification Policy: review on the web before submitting proposal
Check Approved Project List

https://www.vqi.org/data-analysis/rac-approved-project-search/

To submit a proposal to be considered for the National RAC, please follow the link below:
http://abstracts123.com/svs1/meetinglogin
RAC Update: Emily Spangler, MD

- Nicholas Osborne, MD (Univ of Michigan) FIRST chair of the new Venous RAC
- Arterial RAC and Venous RAC alternate months for submissions:
Appointments of Vice-Chairs to the VQC and VRAC
   – Dr. Mark Iafrati has been nominated to serve as Vice Chair of the Venous Quality Council
   – Dr. Fedor Lurie has been nominated to serve as Vice Chair of the Venous RAC

Unblinding EVAR Imaging LTFU: Needs to be voted on by each region

Dr. Goodney presented VISION reporting on EVAR Survival, Reintervention, and Surveillance

The GC discussed the impact to moving to virtual regional meetings and ways to make calls more interactive.

Dr. Beck is the new Vice-Chair of the Executive Committee

The PSO will be appointing 2 new at-large members to the PSO Executive Committee
M2S Updates

Fall 2020
Regional Group Meetings
VQI Technology Updates
Technology Released in Q1 2020

• Barcode scanning feature for PVI device capture
  – Released on **2/26/2020**
  – This new feature can be used to enter device information for all treatment types where the Product Number or DI is required (i.e., excludes plain balloons).
  – This feature is designed to make device entry easier and more efficient for users who have access to a scanner, but the use of this feature is optional. Users may continue to manually enter device product codes and UDIs (unique device identifiers).
Hemodialysis Access (HemoDA) minor revision

- Released on 3/26/2020
- Demographics tab:
  - GFR (eGFR): The GFR numeric field will not allow decimal values. If a decimal value is entered, the value will be automatically rounded to the nearest whole number.
  - PAD: "None" has been added to options.
  - HTN: Updated help text and criteria.
- History tab:
  - Central Venous Dialysis Catheter Chest: "None" has been added to options.
- Procedure tab:
  - Intraoperative Target Artery Diameter: Field updates to retire drop-down options and require numeric entry. One decimal value allowed, the value will be automatically rounded to the nearest tenth. Min/max range values are dependent on the selected Inflow Artery.
Hemodialysis Access (HemoDA) minor revision (continued)

- Procedure tab:
  - Intraoperative Target Vein Diameter: Field updates to retire drop-down options and require numeric entry. One decimal value allowed, the value will be automatically rounded to the nearest tenth. Min/max range values are dependent on the selected Inflow Artery.

- Post-Op tab:
  - Periop Antibiotics: 3 new antibiotic fields have been added ("1st 2nd Gen Cephalosporin", "Start <1hr Pre-op" and "Stop <24hr Post-op").
Across-registry revision Q2 2020
- Released on 4/9/2020
- Hypertension Harmonization
  - The Hypertension field (in the Demographics tab) was updated to align with current clinical guidelines. Help text and select options are being updated in the CAS, CEA, EVAR, IVC, Infra, LEA, Open AAA, PVI, Supra, TEVAR, VMC, and VUR registries as follows:
    • New Help Text: “Hypertension = documented in History or recorded blood pressure $\geq 130/80$ (elevation of either systolic or diastolic) on 3 or more occasions. No = no hypertension Yes, controlled = HTN treated with medication, but BP $< 130/80$ deemed in control; Yes, uncontrolled = HTN not adequately controlled, typically $\geq 130/80$ (elevation of either systolic or diastolic) on two occasions.”
    • New select options are: “No”, “Yes, controlled”, or “Yes, uncontrolled.” The former option “Yes ($\geq 140/90$ or history) was retired.
• **Across-registry revision Q2 2020 (continued)**
  
  – **Antibiotics Harmonization**

  • Data fields to collect Peri-op antibiotics in the Post-Op tab for the CEA, EVAR, Infra, Open AAA, Supra and TEVAR registries were retired and replaced with new data fields as described below. Peri-op antibiotics were not previously captured in the LEA registry, but the new set of fields were also added to the Post-op section of the amputation registry. Please review new help text associated with these fields.

  – The new subset of data fields are as follows:
    
    » “1st 2nd Gen Cephalosporin”
    
    » “Start <1hr Pre-op” (Displayed only if 1st 2nd Gen Cephalosporin is Yes.)
    
    » “Stop <24hr Post-op” (Displayed only if 1st 2nd Gen Cephalosporin is Yes.)
• Across-registry revision Q2 2020 (continued)
  – Free text fields to capture details of “Other” Devices:
  • The VQI updated several registries to add free text fields, labeled as “Please Specify Other Device(s)”, to capture specific device details when “Other” is selected in device lists.
    – CEA: to capture “other” Patch Manufacturer in Procedure tab
    – CAS: to capture “other” EPD Type and “other” Flow Reversal Type in Procedure tab for lesions 1 and 2
    – EVAR: to capture “other” Anchors Used in Procedure and Re-Tx tab and on Follow-up Re-Tx 1, Re-Tx 2, and Re-Tx 3 tabs
    – IVC Filter: to capture “other” Device Manufacturer and “other” Filter Type in Procedure tab.
    – TEVAR: to capture “other” Anchor Type in Aortic Devices and Re-Tx tab and on Follow-up Re-Tx 1 and Re-Tx 2 tabs
• **TEVAR Revision Q2 2020**
  – Released on **4/29/2020**
  – Procedure Tab:
    • Sheath size and closure device information will now be captured for right, left or bilateral access. The new fields appear once an “Access” type other than “None” has been selected.
      – Largest Sheath Size (Fr) - The largest French sheath size used by side. There is a Min/Max range of 16-30. (A table with sheath sizes is included in the help text)
      – Number of Closure Devices - The number of closure devices used by side (0 to >5).
      – Closure Device Type – The brand name of the closure device(s) used at the access site. This field will appear if “Number of Closure Devices” is greater than zero.
      – Specify Other - If “Other” is selected as the “Closure Device Type” this field will appear. Please enter manufacturer and device details by free-text.
• **TEVAR Revision Q2 2020 (continued)**
  
  – **Post-Op Tab:**
    
    • Several fields were updated or retired and replaced with new access side-specific data fields and options.
      
      – Complications section: These new fields will only display for right and/or left access once an access type other than “None” has been selected for the given side on the procedure tab.
        
        » Access Site Hematoma / Pseudoaneurysm – The most extensive treatment of hematoma or pseudoaneurysm by side.
        
        » Access Site Occlusion – The most extensive treatment for the occlusion by side.
        
        » Access Site Infection – The depth and involvement of infection by side.
      
      – The new fields above replaced the following, which were retired:
        
        » Puncture Site Hematoma
        
        » Access Site Occlusion
        
        » Surgical Site Infection
TEVAR Revision Q2 2020 (continued)

Post-Op Tab:

- Re-intervention section:
  - Indication (Re-Tx) – The “Access Related” option was retired and new options to indicate “Right access related” and “Left access related” were added.
Technology Released in Q2 2020

- **PVI revision in Q2 2020**
  - Released on **6/29/2020**
  - **Demographics Tab:**
    - The “Ambulation” field will no longer appear if the “Bed bound” option is chosen for the “Functional Status” field. Previously the “Ambulation” field displayed and defaulted to “Bedridden”. This change was applied to both the Demographics tab in the procedure form, as well as in the Long Term Follow-up form. The existing select option of “Bedridden” for the “Ambulation” field no longer appears on the form with this new dependency.
  - **Procedure Tab:**
    - Closure Device fields: The following fields were added for both access sites, in both the Basic and Comprehensive PVI forms:
      - “Number of Closure Devices”, with the options: “1, 2, 3, and >3”.
      - “Closure Outcome”, with the options: “Closure device successful; Closure device failed; Closure device failed, intervention; and Closure device failed, surgery”.
    - The “Closure Device Successful” field was retired, and appears in the Data Download files preceded with “R-” (R- Closure Device Successful).
PVI revision in Q2 2020 (continued)

Post-Procedure Tab:

- "Hematoma" field: The select options for the existing Hematoma fields (for access site 1 and 2 as applicable) were expanded for greater accuracy.
  - The following Hematoma options were maintained: "No, Minor, Transfusion and Thrombin injection".
  - The prior "Surgical Rx" option was re-named "Surgical Re-Tx (intra-op or post-op)"
  - One new option was added: "Interventional Re-Tx (intra-op or post-op)".

- The "Right/Left Amputation Level" fields no longer appear if the "No" option is chosen for the "Amputation During Admission" field. The existing select option of "No" for the "Right and Left Amputation Level" fields no longer appear on the form with this new dependency.
Add PVI Procedure Context variables to Follow-up data download file

- Released on **6/29/2020**
- In response to member feedback, the VQI added two new columns to the PVI Follow-up data download file to identify the specific arteries and sides treated as selected on the procedure form and displayed in the PATHWAYS follow-up form.

  - The new columns appear before the “Current Patency” fields in the PVI Long Term Follow-up Data Download file. Follow-Up Data Download file additional columns:
    - “Arteries Treated”
    - “Side”

  - The columns appear in groups by field: “Artery Treated 1, Artery Treated 2, Artery Treated 3, Artery Treated 4.., then Side 1, Side 2, Side 3, ..., then Current Patency 1, Current Patency 2”, etc.
VSR diameter unit change mm² -> mm and related help text updates

- Released on 7/15/2020
- The units associated with the “Minimal Diameter Within Stenosis” and “Minimal Diameter at Reference Location” fields were changed from “mm²” to “mm”.

![Image of VSR technology interface](image_url)
Hemodialysis Access (HemoDA) revision for tapered graft

- Released on **7/29/2020**
- Three new fields were added to the HDA registry to capture “Tapered Devices”. A new "Tapered Device" field was added to the Procedure tab in the Conduit Details section. If “Yes” is selected for the “Tapered Graft” field, then two new diameter fields display: “Tapered Graft Minimum Diameter” and “Tapered Graft Maximum Diameter”.

![Image of HDA registry with new fields added for tapered devices]
Revised COVID-19 message for Follow-up Mandatory Fields

- Released on 7/29/2020
- The VQI added a temporary message about the impact of COVID-19 on LTFU completion rate calculations. The following message is displayed when submitting a LTFU that is missing any mandatory variable:
  - "IMPORTANT: The PSO understands that routine follow up visits may not be possible due to COVID-19 state mandates. Special considerations will be part of our LTFU calculation for 2020, please collect all of the required fields that are possible during this time."
- As a reminder, the VQI allows phone and telehealth appointments to be used for LTFU when Face-to-Face visits are not feasible.
• “Was this helpful?” feature for Help Text
  – Released on **7/29/2020**
  – This new feature is to provide feedback regarding the current help text. For each help text field, users will have the option to indicate if the help text provided was useful or not. This information will help the VQI to identify data fields that may be unclear to members.
  – The “Was this helpful?” vote up/down button displays in the bottom right corner of the help text box:
Other Projects in Progress

- Across-registry revision to add COVID-19 variables
- TEVAR Revision to align with SVS/STS guidelines
- Vascular Ultrasound Registry (VUR) major revision
- Varicose Vein Registry (VVR) revision for New CEAP Clinical Classification
- Venous Stent Registry (VSR) revision for New CEAP Clinical Classification
- Vascular Medicine Consult (VMC) registry revision to add new drug category and update CAD
- VQI PRO collection for PVI
Registry Projects
These projects are conducted within the SVS PSO and only non-identifiable data (removal of patient, center and physician information) will be provided to Medtronic/BARD/Cook/Gore or the FDA. Only standard of care practice is being evaluated. For such PSO activities, patient informed consent and Institutional Review Board review are not required.

Sites must follow their institutional guidelines.
TEVAR Dissection Surveillance Project is Open for Enrollment

- The SVS PSO is excited to announce the reopening of the TEVAR Dissection Surveillance Project to evaluate the Cook Zenith Dissection Endovascular System. FDA approval was granted for this device after safety and effectiveness were demonstrated in pre-market studies of complicated dissection with the proviso that the efficacy of TEVAR treatment of descending aortic dissection would be more fully analyzed through post-market surveillance, as was done through VQI for the W. L. Gore and Medtronic devices after their approval.

- Patients will have 30 day, and annual visits for 5 years.
- Total reimbursement of $4,000 per patient for a patient followed annually for 5 years
TEVAR Dissection Surveillance Project is Open for Enrollment

- 0 of the 180 required patients enrolled (5 potential cases in process)
  - Retrospective enrollment allowed- All eligible cases from December 31, 2018 (protocol FDA approval date)
- 12 of 40 sites enrolled (11 more in contracting)
  - This project is conducted within the SVS PSO and only non-identifiable data (removal of patient, center and physician information) will be provided to Medtronic or the FDA. Only standard of care practice is being evaluated. For such PSO activities, patient informed consent and Institutional Review Board review are not required.

For more information, please contact: tevarproject@m2s.com
PVI Post-Market Surveillance Projects

Medtronic IN.PACT® Admiral® DCB ISR Project

Medtronic

The Bard® LifeStent® Popliteal Artery Stent Project

Bard

Objective: To conduct long term post-market surveillance of the safety and effectiveness of the Bard® LifeStent® Vascular Stent Systems for the treatment of symptomatic de novo or restenotic lesions in the popliteal artery.

Patients will have 12 month and a 24 month follow up visits.

Total reimbursement of $1,400 per patient for a patient followed annually for 2 years

2 additional fields added:

- Check box to indicate that patient is eligible to enroll project based on the inclusion and exclusion criteria.
- Post-procedure – site will be asked if the patient has had a stroke.
- Angios performed at re-intervention and sent to M2S.
Bard® LifeStent® Popliteal Artery Stent

Enrollment Complete

• 74 of the 74 required patients enrolled
  – Retrospective enrollment allowed- All eligible cases from 10/1/2016 (protocol FDA approval date)

• 29 of 30 sites enrolled
  – This project is conducted within the SVS PSO and only non-identifiable data (removal of patient, center and physician information) will be provided to Bard or the FDA. Only standard of care practice is being evaluated. For such PSO activities, patient informed consent and Institutional Review Board review are not required.
The Medtronic IN.PACT® Admiral® DCB ISR Project Post-market registry surveillance of the clinical use of the Medtronic IN.PACT® Admiral® Paclitaxel-Coated PTA Balloon.

Objective: To assess the long-term safety and performance of the IN.PACT® Admiral® DCB in a U.S. population for the treatment of ISR lesions in the superficial femoral and popliteal arteries.

Patients will be followed at 12, 24 and 36 months.

Total reimbursement of $1,950 per patient for a patient followed annually for 3 years.

1 additional field added:
   – Check box to indicate that patient is eligible to enroll project based on the inclusion and exclusion criteria.
Enrollment Complete

• 300 of the 300 required patients enrolled
  – Retrospective enrollment allowed- All eligible cases from December 6, 2016 (protocol FDA approval date)

• 50 of 50 sites enrolled
  – This project is conducted within the SVS PSO and only non-identifiable data (removal of patient, center and physician information) will be provided to Medtronic or the FDA. Only standard of care practice is being evaluated. For such PSO activities, patient informed consent and Institutional Review Board review are not required.
For More Information Contact:

**Medtronic IN.PACT® Admiral® DCB ISR Project**
Anita Duxbury  
[MedtronicAdmiralDCB@m2s.com](mailto:MedtronicAdmiralDCB@m2s.com)

**The Bard® LifeStent® Popliteal Artery Stent Project**
Charlotte Stirewalt  
[BardLifeStent@m2s.com](mailto:BardLifeStent@m2s.com)
PATHWAYS Support
2019 Claims Validation
The 2019 Claims Validation process was launched in July.
• All hospital managers and physicians at selected centers have been notified.
• The list of centers selected to participate in the 2019 validation cycle is posted to the Resources in PATHWAYS.
• An interactive claims validation webinar will be announced soon and will be recorded for future reference.

PATHWAYS Educational Webinars
• A reporting webinar series (2 sessions) will be scheduled in the Fall.
• Visit the Resources tab in PATHWAYS to access previously recorded webinars.
PATHWAYS Support

PATHWAYS Communication

We understand that some members do not always receive mass emails from M2S, due to firewall and spam filter configurations at their centers. In an effort to ensure that all members are aware of important registry updates, we’ve taken the following steps:

• Each announcement that we send will indicate which user groups it was sent to.

• A notification is posted in PATHWAYS with a link to each announcement sent for all centers impacted by the update.

• Please make sure you review the notices that pop up on your PATHWAYS screen to see important reminders and abstraction tips also!
Meeting Evaluation

- What did you like about this meeting?
- What can we do better?
- Next meeting location?
  - Grant funding issues with Industry
  - Remote?
Participation Award Credit

• PLEASE SIGN INTO RING CENTRAL MEETING with your FULL NAME to get CREDIT for ATTENDANCE! (no exceptions will be made)

More than one of you in a room? Email Leka Johnson @ ljohnson@svspso.org to get credit

• So Again............You have 7 days!!!

For CME/CE credit, please click this link:
https://dmu.co1.qualtrics.com/jfe/form/SV_dj3nVgjPUKzVORL

Complete both parts of the form and Don’t forget to hit SUBMIT for credit!